Flow Cytometry Immunophenotyping is the Diagnostic Assay for CLL
Flow cytometry of peripheral blood demonstrating the characteristic CLL immunophenotype is the definitive diagnostic assay and is sufficient for diagnosis without requiring bone marrow biopsy. 1, 2, 3
Diagnostic Criteria
The diagnosis requires:
- ≥5 × 10⁹/L monoclonal B lymphocytes in peripheral blood 1, 2, 3
- Clonality confirmed by flow cytometry showing light chain restriction (kappa or lambda) 1, 2
Required Immunophenotype Pattern
CLL cells must demonstrate this specific profile on flow cytometry 1, 2, 4:
Positive markers:
- CD5 (co-expressed with B-cell antigens)
- CD19
- CD20 (characteristically dim/low)
- CD23
- CD43 (bright)
- CD200
Characteristically low/dim expression:
- Surface immunoglobulin (dim)
- CD79b (dim to negative)
- CD22 (dim)
Monoclonal light chain restriction:
- Either kappa OR lambda (not both)
Why Flow Cytometry is Sufficient
The guidelines are explicit that bone marrow biopsy is NOT required for diagnosis 1, 2, 3. Flow cytometry alone provides:
- Definitive diagnosis through the characteristic immunophenotype
- Differentiation from other lymphoproliferative disorders, particularly mantle cell lymphoma (which typically lacks CD23 despite expressing CD5) 1, 2
- Immediate diagnostic certainty without invasive procedures
When Additional Testing is Needed
Lymph node biopsy is only indicated when 2:
- Immunophenotyping is inconclusive
- Diagnosing small lymphocytic lymphoma (SLL) variant with <5 × 10⁹/L circulating cells but lymphadenopathy
Bone marrow biopsy is reserved for 1, 2:
- Unexplained cytopenias requiring evaluation
- Before initiating myelosuppressive therapies
- Confirming complete remission in clinical trials
Critical Pitfall to Avoid
Do not confuse diagnostic testing with prognostic testing. While FISH for del(17p)/del(11q), TP53 mutation analysis, and IGHV mutational status are essential for treatment planning 1, 3, 5, these are not diagnostic assays—they are performed after diagnosis is established by flow cytometry to guide prognosis and therapy selection.
The morphologic finding of small, mature lymphocytes with narrow cytoplasm and dense nuclei on blood smear supports the diagnosis but flow cytometry immunophenotyping remains the gold standard confirmatory test 1, 2.